Biotech News

Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders

Pacira BioSciences (PCRX)Pacira BioSciences2026-04-28 20:20 ESTCompany update

Urges Stockholders to Vote “FOR” Pacira’s Highly Qualified Nominees on the BLUE Proxy Card Today Strongly Opposes the Election of Each of DOMA’s Underqualified Nominees BRISBANE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the

Pacira BioSciences

Non-Opioid Pain Management Pacira BioSciences develops and commercializes non-opioid therapies for postsurgical and musculoskeletal pain. Its portfolio combines extended-release pharmaceuticals, a cryoanalgesia device and a locally administered gene-therapy program. EXPAREL EXPAREL is a multivesicular-liposome formulation of bupivacaine...

Recent company news

PCRXPacira BioSciences2026-08-07 12:00 EST

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PCRXPacira BioSciences2026-08-06 12:00 EST

Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases

PCRXPacira BioSciences2026-08-04 20:01 EST

Pacira BioSciences Reports Second Quarter 2026 Financial Results

PCRXPacira BioSciences2026-07-28 12:00 EST

Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce

PCRXPacira BioSciences2026-07-27 12:00 EST

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

Stock data

Close: 24.67 USD
Market cap: 875.49M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States